A process for preparing a sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1′,2′:4,5] pyrazino[2,1-b][1,3]oxazepin-8-olate of Formula 1 and its polymorphic form thereof.

##STR00001##

A process for preparing a sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1′,2′:4,5] pyrazino[2,1-b][1,3]oxazepin-8-olate of Formula 1 and its polymorphic form thereof.

##STR00001##

This invention provides humanized IgG4 monoclonal antibodies having the light and heavy chain variable region amino acid sequences of PRO 140, wherein the antibody comprises (i) a heavy chain modification that inhibits half antibody formation, (ii) a heavy chain modification that increases the antibody's terminal half-life, and, optionally, (iii) a heavy chain modification that lowers the antibody's effector function. This invention also provides a related humanized IgG2/IgG4 monoclonal fusion antibody. This invention further provides related nucleic acid molecules; recombinant vectors; recombinant AAV particles; pharmaceutical compositions; prophylactic and therapeutic methods for addressing HIV-1 infection, SARS-CoV-2 infection, and CCR5-mediated disorders; and kits for performing these methods.

This invention provides humanized IgG4 monoclonal antibodies having the light and heavy chain variable region amino acid sequences of PRO 140, wherein the antibody comprises (i) a heavy chain modification that inhibits half antibody formation, (ii) a heavy chain modification that increases the antibody's terminal half-life, and, optionally, (iii) a heavy chain modification that lowers the antibody's effector function. This invention also provides a related humanized IgG2/IgG4 monoclonal fusion antibody. This invention further provides related nucleic acid molecules; recombinant vectors; recombinant AAV particles; pharmaceutical compositions; prophylactic and therapeutic methods for addressing HIV-1 infection, SARS-CoV-2 infection, and CCR5-mediated disorders; and kits for performing these methods.

Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

##STR00001##

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Tumor Suppressor genes.

Large molecular weight alginates which are covalently modified to store and release nitric oxide, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates may be tailored to release nitric oxide in a controlled manner and are useful for eradication of both planktonic and biofilm-based bacteria.

The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.